Establishment Labs (NASDAQ:ESTA) Sets New 12-Month High – Here’s What Happened

Establishment Labs Holdings Inc. (NASDAQ:ESTA) shares hit a new 52-week high on Thursday . The stock traded as high as $83.78 and last traded at $83.1170, with a volume of 293524 shares traded. The stock had previously closed at $79.46.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Friday, March 27th. Wall Street Zen cut Establishment Labs from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Needham & Company LLC raised their price objective on Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a research note on Wednesday, May 6th. Finally, TD Cowen reissued a “buy” rating on shares of Establishment Labs in a research report on Monday. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $87.14.

Establishment Labs Stock Performance

The company has a quick ratio of 1.91, a current ratio of 2.96 and a debt-to-equity ratio of 16.82. The company has a market capitalization of $2.51 billion, a PE ratio of -57.21 and a beta of 1.11. The business has a 50 day simple moving average of $67.77 and a 200 day simple moving average of $68.96.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The business had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.Establishment Labs’s revenue was up 44.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.70) EPS. Equities research analysts predict that Establishment Labs Holdings Inc. will post -1.07 EPS for the current fiscal year.

Insider Buying and Selling at Establishment Labs

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the sale, the director directly owned 927,504 shares of the company’s stock, valued at $69,952,351.68. The trade was a 10.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 330,000 shares of company stock worth $22,854,538 over the last 90 days. 9.99% of the stock is owned by insiders.

Hedge Funds Weigh In On Establishment Labs

Several hedge funds and other institutional investors have recently bought and sold shares of ESTA. KBC Group NV acquired a new stake in Establishment Labs during the 1st quarter valued at approximately $28,000. Quarry LP purchased a new position in shares of Establishment Labs during the third quarter worth $34,000. Kestra Advisory Services LLC acquired a new position in Establishment Labs during the fourth quarter valued at $47,000. State of Wyoming purchased a new stake in Establishment Labs in the third quarter valued at $71,000. Finally, Osaic Holdings Inc. raised its stake in shares of Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after buying an additional 1,800 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.